CNR (Institut Pasteur) approval in France
Ministry of Health approval in Thailand
Paris, France and Camberley, UK – 6 April 2020 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that the CNR (Centre National de Référence des Virus des Infections Respiratoires (dont la grippe)) of the Institut Pasteur, an internationally renowned centre for biomedical research with a goal of improving public health in France, has approved its COVID-19 test. The Company’s CE-Mark test is available for immediate distribution into the French market.
On 2 April 2020, Novacyt also received approval for its COVID-19 test from the Ministry of Health in Thailand.
Graham Mullis, Chief Executive Officer of Novacyt, commented:
“As an Anglo-French company, I am delighted that Novacyt is able to support both of its domestic markets in tackling this pandemic. The Institut Pasteur’s evaluation and approval of our COVID-19 test is an important validation and I am grateful to Atothis, our distribution partner in France, for its efforts in working with the centre. We look forward to suppo rting the French authorities in their COVID-19 testing requirements. ”
The Primerdesign COVID-19 test has received accreditation from a number of leading global regulatory authorities, including Public Health England and the US Food and Drug Administration. In addition to the test currently being approved in the UK, the US, France, India, the Philippines, Argentina and Thailand, it is available in markets which directly accept CE-Mark accreditation without the need for further approval.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
